Paratek Pharmaceuticals and Radius Health Combination Supported by $1.3B Financing Led by Blackstone Credit & Insurance

B-FLEXION Life Sciences to Acquire Remaining 57% of Radius Health from Patient Square and Webster Equity Partners

January 12, 2026

Pharmaceuticals

B-FLEXION Life Sciences has agreed to purchase the remaining 57% interest in Radius Health held by affiliates of Patient Square Capital and Webster Equity Partners. Radius, a specialty biopharmaceutical focused on bone health, had been taken private by B-FLEXION and Patient Square in August 2022. The transaction is expected to close by the end of Q1 2026.

Gurnet Point Capital and Patient Square Capital Acquire Radius Health

June 23, 2022

Healthcare Services

Gurnet Point Capital and Patient Square Capital entered into a definitive agreement to acquire Radius Health in a transaction valued at approximately $890 million, including the assumption of debt. The offer is $10.00 per share in cash plus a $1.00 per share contingent value right (CVR) tied to TYMLOS (abaloparatide) net sales reaching $300 million during a 12-month period prior to December 31, 2025.

Gurnet Point Capital and Novo Holdings Acquire Paratek Pharmaceuticals

September 21, 2023

Pharmaceuticals

Gurnet Point Capital and Novo Holdings completed the acquisition of Paratek Pharmaceuticals for $2.15 per share in cash plus a $0.85 CVR tied to NUZYRA sales, in a transaction valued at approximately $462 million including assumed debt. Oaktree provided $175 million of debt financing; following closing Paratek will be taken private and delisted from Nasdaq as the buyers aim to accelerate commercialization of NUZYRA and expand Paratek's anti-infective portfolio.

BlackRock LTPC Acquires Majority Stake in Paradigm Oral Health

September 22, 2022

Healthcare Services

BlackRock Long Term Private Capital (LTPC) has entered into a definitive agreement to acquire a majority interest in Paradigm Oral Health from shareholders including InTandem Capital Partners. The investment will partner with Paradigm's executive team, led by founder and CEO Dr. David Rallis, to support platform expansion, technology adoption and continued growth of the company's oral surgery and digital dentistry platform.

Permira Partners with Marcucci Family, ADIA and Ampersand to Combine Kedrion and BPL

September 1, 2022

Pharmaceuticals

Funds advised by Permira, in partnership with the Marcucci family and supported by a subsidiary of ADIA and Ampersand Capital Partners, completed the joint acquisition and combination of Kedrion Biopharma and Bio Products Laboratory (BPL) to create a global leader in plasma derivatives and rare disease medicines. The combined company will be headquartered in Italy, generate over €1.1 billion in revenue, and expand its global footprint (including a ~75 US plasma center footprint); Ugo Di Francesco has been appointed CEO effective January 2023.

AgencyBloc Acquires Radius

February 1, 2023

Cloud & SaaS

AgencyBloc, a Resurgens-backed agency management system provider, has acquired Radius, a Las Vegas-based sales enablement provider for life and health insurance brokers. The add-on expands AgencyBloc's sales enablement capabilities — including lead distribution, texting and integrated VoIP/call routing — to accelerate its vision of a single, end-to-end platform for brokers and high-volume organizations.